Experimental Smallpox Vaccine Put on Fast Track

The U.S. Food and Drug Administration has awarded “fast track” status to a smallpox vaccine being developed by the pharmaceutical firm Acambis, the company announced today (see GSN, Dec. 10).

The decision means the agency will work to expedite approval of the ACAM2000 vaccine, Acambis said in a press release. More than 180 million doses of the vaccine have been added to the U.S. Strategic National Stockpile for emergency use (Acambis press release, Jan. 5).

Back to top
About Newswire  |  Contact National Journal  |  Re-Use Guidelines © Copyright 2008 by National Journal Group, Inc. The material in this section is produced independently for NTI by National Journal Group, Inc. Any reproduction or retransmission, in whole or in part, is a violation of federal law and is strictly prohibited without the consent of the National Journal Group, Inc. All rights reserved.